Hyperuricemia and prognosis in chronic kidney disease
Full Text:PDF (Українська)
Richette P, Doherty M, Pascual E, et al. EXTENDED REPORT 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016 July 25. doi: 10.1136/annrheumdis-2016-209707.
Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Therapeutic AdvancesinMusculoskeletal Disease. 2016;8(4):145-59. doi: 10.1177/1759720X16646703.
Kravchun PG, Krapivko SA, Kravchun PP, Kadykova OI. Influence of magnesium orotate on lipid metabolism in patients with chronic heart failure with concomitant type 2 diabetes mellitus. International Journal of Endocrinology.2012;2(42):12-6. (In Russian).
Shen JI, Saxena AB, Vangala S, Dhaliwal SK, Winkelmayer WC. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study. BMC Nephrology. 2017 Jun 17;18(1):196.doi: 10.1186/s12882-017-0616-4.
Hozhenko AI, Kravchuk AV, Sirman VM, Nikitenko OP, Romaniv LV. Functional renal reserve: physiological value of renal reserve and substantiation of the method of its determination. Pochki. 2015;4(14):7-11. (In Ukrainian). doi: 10.22141/2307- 12188.8.131.52.2015.74890.
Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. Rheumatology (Oxford, England). 2011;50(4):740-5. doi: 10.1093/rheumatology/keq346.
Savytska LM. The correlation between renal functional reserve and serum uric acid and quality of life in chronic kidney disease stage I–III. Pochki. 2017; 6(2):99-104. (In Ukrainian). doi: 10.22141/2307-12184.108.40.2067.102788.
- There are currently no refbacks.
Copyright (c) 2017 KIDNEYS
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2018